Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24 months and immunogenicity of a fifth dose administered at 4 years of age-a phase 3 extension to a randomised controlled trial

Abstract

Waning of protective antibodies occurred 24–36 months after toddler booster regardless of age at boost. This was least marked against target strains 5/99 and M10713. A robust memory response occurred after a booster dose given at 4 years of age.

Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedules

“…29 Similar persistence of antibodies at 4 years of age has been described in children after 3 infant doses of vaccine and a booster in the second year of life. 20 This suggests that 3 doses in infants and a booster is broadly equivalent to 2 doses in the second year of life with respect to antibody persistence to 4 years. However, this latter regime provides no protection to young infants who have the highest incidence of disease.…”

“…20 We invited participants who were involved in a previous followup study to take part in this study via an invitation letter. In the previous study, 3 cohorts received 2 doses of 4CMenB at 12 and 14 months (n = 239), 18 and 20 months (n = 51) or 24 and 26 months (n = 55).…”

Potential benefits of using a multicomponent vaccine for prevention of serogroup B meningococcal disease

“…Antibody persistence has been evaluated up to 36 months following vaccination during infancy. hSBA titers 5 across vaccine antigens were found to be maintained for 9-97% and 10-90% of children vaccinated according to a 3 + 1 schedule at 2, 4, 6, and 12 months and 2, 3, 4, and 12 months of age, respectively (Iro et al, 2017). A study comparing 2 + 1 (at 3.5, 5, and 11 months or 6, 8, and 11 months of age) and 3 + 1 schedules (at 2.5, 3.5, 5, and 11 months of age) showed that similar percentages of children (38-93% and 36-84%) maintained hSBA titers 4 at 24-36 month postvaccination (Martinon-Torres et al, 2018).…”

Disparities in healthcare providers’ interpretations and implementations of ACIP’s meningococcal vaccine recommendations

“…Healthcare providers who completed the survey and reviewed at least 4 patient charts received an honorarium of $75 plus $15 per additional patient chart. The study was reviewed and approved by the Pearl Institutional Review Board 43 (4).…”